These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23333302)

  • 1. Nanotoxicological classification system (NCS) - a guide for the risk-benefit assessment of nanoparticulate drug delivery systems.
    Keck CM; Müller RH
    Eur J Pharm Biopharm; 2013 Aug; 84(3):445-8. PubMed ID: 23333302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications.
    Fadeel B; Garcia-Bennett AE
    Adv Drug Deliv Rev; 2010 Mar; 62(3):362-74. PubMed ID: 19900497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters.
    Gaumet M; Vargas A; Gurny R; Delie F
    Eur J Pharm Biopharm; 2008 May; 69(1):1-9. PubMed ID: 17826969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid Nanoparticles and their Application in Nanomedicine.
    Rajabi M; Mousa SA
    Curr Pharm Biotechnol; 2016; 17(8):662-72. PubMed ID: 27087491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine and veterinary science: the reality and the practicality.
    Underwood C; van Eps AW
    Vet J; 2012 Jul; 193(1):12-23. PubMed ID: 22365842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern.
    Lam PL; Wong WY; Bian Z; Chui CH; Gambari R
    Nanomedicine (Lond); 2017 Feb; 12(4):357-385. PubMed ID: 28078952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotoxicity and the importance of being earnest.
    Vorup-Jensen T; Peer D
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1661-2. PubMed ID: 23000008
    [No Abstract]   [Full Text] [Related]  

  • 8. Unique benefits of nanotechnology to drug delivery and diagnostics.
    McNeil SE
    Methods Mol Biol; 2011; 697():3-8. PubMed ID: 21116949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for nanoparticle surface reactivity in facilitating pulmonary toxicity and development of a base set of hazard assays as a component of nanoparticle risk management.
    Warheit DB; Reed KL; Sayes CM
    Inhal Toxicol; 2009 Jul; 21 Suppl 1():61-7. PubMed ID: 19558235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 1. Drug/gene delivery applications.
    Son SJ; Bai X; Lee SB
    Drug Discov Today; 2007 Aug; 12(15-16):650-6. PubMed ID: 17706547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicology of nanoparticles.
    Elsaesser A; Howard CV
    Adv Drug Deliv Rev; 2012 Feb; 64(2):129-37. PubMed ID: 21925220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology.
    Ilinskaya AN; Dobrovolskaia MA
    Nanomedicine (Lond); 2013 May; 8(5):773-84. PubMed ID: 23656264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery.
    Katara R; Majumdar DK
    Colloids Surf B Biointerfaces; 2013 Mar; 103():455-62. PubMed ID: 23261566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaginal drug delivery: strategies and concerns in polymeric nanoparticle development.
    Wong TW; Dhanawat M; Rathbone MJ
    Expert Opin Drug Deliv; 2014 Sep; 11(9):1419-34. PubMed ID: 24960192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Composite nanoparticles take aim at cancer.
    Gil PR; Parak WJ
    ACS Nano; 2008 Nov; 2(11):2200-5. PubMed ID: 19206383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolving the nanoparticles paradox.
    Donaldson K
    Nanomedicine (Lond); 2006 Aug; 1(2):229-34. PubMed ID: 17716112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.
    Lanza GM; Winter PM; Caruthers SD; Hughes MS; Cyrus T; Marsh JN; Neubauer AM; Partlow KC; Wickline SA
    Nanomedicine (Lond); 2006 Oct; 1(3):321-9. PubMed ID: 17716162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells.
    Maya S; Kumar LG; Sarmento B; Sanoj Rejinold N; Menon D; Nair SV; Jayakumar R
    Carbohydr Polym; 2013 Apr; 93(2):661-9. PubMed ID: 23499109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming in vivo barriers to targeted nanodelivery.
    Chrastina A; Massey KA; Schnitzer JE
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(4):421-37. PubMed ID: 21538941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.